News & Views | Published:

Noncoding RNAs as effective markers in cancer-care management

Nature Medicine volume 23, pages 11221123 (2017) | Download Citation

Two recent studies show that 'silent' variants can modulate regulatory circuits, including those in noncoding RNAs, affecting cancer predisposition and drug sensitivity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Nat. Rev. Drug Discov. 12, 358–369 (2013).

  2. 2.

    Am. J. Hum. Genet. 94, 559–573 (2014).

  3. 3.

    et al. Nat. Med. 23, 1167–1175 (2017).

  4. 4.

    et al. Nat. Med. 23, 1226–1233 (2017).

  5. 5.

    et al. Exp. Cell Res. 279, 177–187 (2002).

  6. 6.

    , & CA Cancer J. Clin. 65, 401–421 (2015).

  7. 7.

    Int. J. Clin. Exp. Pathol. 8, 11884–11894 (2015).

  8. 8.

    et al. Cancer Epidemiol. Biomarkers Prev. 12, 103–113 (2003).

  9. 9.

    et al. Cancer Chemother. Pharmacol. 63, 139–148 (2008).

  10. 10.

    Nat. Med. 21, 1253–1261 (2015).

Download references

Acknowledgements

M.H. and I.R. are supported by the European Research Council Starting Grant 281877 and the Spanish Ministry of Science Grant BFU2014-58027-R.

Author information

Affiliations

  1. Ivan Raimond and Maite Huarte are in the Department of Gene Therapy and Regulation of Gene Expression, Center for Applied Medical Research, University of Navarra, Pamplona, Spain, and the Institute of Health Research of Navarra (IdiSNA), Pamplona, Spain.

    • Ivan Raimondi
    •  & Maite Huarte

Authors

  1. Search for Ivan Raimondi in:

  2. Search for Maite Huarte in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Maite Huarte.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.4423

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing